{"id":"combination-bupropion-nrts","safety":{"commonSideEffects":[{"rate":"30–40","effect":"Insomnia"},{"rate":"10–20","effect":"Dry mouth"},{"rate":"10–15","effect":"Nausea"},{"rate":"10–15","effect":"Headache"},{"rate":"5–10","effect":"Dizziness"},{"rate":"0.4","effect":"Seizures (bupropion)"},{"rate":"5–10","effect":"Skin irritation (NRT patch)"}]},"_chembl":{"chemblId":"CHEMBL1201735","moleculeType":"Small molecule","molecularWeight":"320.66"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bupropion is an atypical antidepressant that increases dopamine and norepinephrine availability in the brain, reducing cravings and withdrawal symptoms during smoking cessation. Nicotine replacement therapies (NRTs—patches, gum, lozenges, nasal spray, or inhalers) deliver controlled doses of nicotine to satisfy physical dependence while avoiding the harmful combustion products of cigarettes. The combination leverages complementary mechanisms: bupropion addresses mood and motivation while NRT manages acute nicotine withdrawal.","oneSentence":"Bupropion inhibits norepinephrine and dopamine reuptake while nicotine replacement therapies provide exogenous nicotine to reduce withdrawal symptoms, together addressing both the neurochemical and behavioral aspects of tobacco dependence.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:40:04.633Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Smoking cessation in adults"}]},"trialDetails":[{"nctId":"NCT02676375","phase":"PHASE4","title":"Nicotine Receptor Density & Response to Nicotine Patch: Pt 2 Extended Treatment","status":"COMPLETED","sponsor":"Brentwood Biomedical Research Institute","startDate":"2014-01","conditions":"Smoking Cessation, Schizophrenia","enrollment":42}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Combination Bupropion + NRTs","genericName":"Combination Bupropion + NRTs","companyName":"Brentwood Biomedical Research Institute","companyId":"brentwood-biomedical-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bupropion, a small molecule inhibitor of the sodium-dependent dopamine transporter, is used in combination with Nicotine Replacement Therapies (NRTs) to aid in smoking cessation. This combination has been studied in clinical trials for smoking cessation and schizophrenia, with extended treatment and home visits and calls also being investigated.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}